

THE LANCET

Gastroenterology & Hepatology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Belli LS, Duvoux C, Karam V, et al. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. *Lancet Gastroenterol Hepatol* 2020; published online June 4. [https://doi.org/10.1016/S2468-1253\(20\)30183-7](https://doi.org/10.1016/S2468-1253(20)30183-7).

	Recipients (n=103)
Presenting symptoms	
Fever	71/102 (70%)
Cough	60/102 (59%)
Polypnoea or dyspnoea	35/102 (34%)
Diarrhoea	24/102 (24%)
Asthenia	20/102 (20%)
Muscle pain	15/102 (15%)
Anosmia or disgeusia	9/102 (9%)
Thoracic pain	7/102 (7%)
Confusion	2/102 (2%)
Others	6/102 (6%)
Co-morbidities	
Overweight (>25 kg/m ²)	49/88 (56%)
Hypertension	52/101 (51%)
Diabetes	41/101 (41%)
Chronic renal impairment (creatinine >2 mg/dL)	15/101 (15%)
History of smoking tobacco	13/101 (13%)
Coronary artery disease	7/101 (7%)
Others	12/101 (12%)
Treatment for COVID-19	
Hydroxychloroquine	63/95 (66%)
Azythromycin	31/95 (33%)
Lopinavir/ritonavir	16/95 (17%)
High-dose steroids	17/95 (18%)
Tocilizumab	7/95 (7%)
Mortality	
Overall	16/103 (16%)
Among males	14/76 (18%)
Among females	2/27 (7%)
Among patients aged ≥60 years	16/73 (22%)
Among males aged ≥60 years	14/59 (24%)
Among patients aged ≤60 years	0/27 (0%)
Among patients on mechanical ventilation	4/9 (44%)
Among those transplanted within the past 2 years	1/21 (5%)
Among those transplanted ≥2 years ago	15/82 (18%)

Data are n/N (%). Denominators vary because of missing data.

Table 1: Data for the first 103 patients in the ELITA/ELTR COVID-19 registry